



**HAL**  
open science

## Brain virtual histology with X-ray phase-contrast tomography Part I: whole-brain myelin mapping in white-matter injury models

Matthieu Chourrout, Hugo Rositi, Elodie Ong, Violaine Hubert, Alexandre Paccalet, Louis Foucault, Awen Autret, Barbara Fayard, Cécile Olivier, Radu Bolbos, et al.

### ► To cite this version:

Matthieu Chourrout, Hugo Rositi, Elodie Ong, Violaine Hubert, Alexandre Paccalet, et al.. Brain virtual histology with X-ray phase-contrast tomography Part I: whole-brain myelin mapping in white-matter injury models. Biomedical optics express, 2022, 13 (3), pp.1620-1639. 10.1364/BOE.438832 . hal-03428448v2

HAL Id: hal-03428448

<https://hal.science/hal-03428448v2>

Submitted on 30 Mar 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.





L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



# Brain virtual histology with X-ray phase-contrast tomography Part I: whole-brain myelin mapping in white-matter injury models

MATTHIEU CHOURROUT,<sup>1,11</sup>  HUGO ROSITI,<sup>2,11</sup> ELODIE ONG,<sup>3,4</sup> VIOLAINE HUBERT,<sup>3</sup> ALEXANDRE PACCALET,<sup>3</sup> LOUIS FOUCAULT,<sup>5</sup> AWEN AUTRET,<sup>6</sup> BARBARA FAYARD,<sup>6</sup> CÉCILE OLIVIER,<sup>7</sup> RADU BOLBOS,<sup>8</sup> FRANÇOISE PEYRIN,<sup>7</sup> CLAIRE CROLA-DA-SILVA,<sup>3</sup> DAVID MEYRONET,<sup>4</sup> OLIVIER RAINETEAU,<sup>5</sup> HÉLÈNE ELLEAUME,<sup>9</sup> EMMANUEL BRUN,<sup>9</sup>  FABIEN CHAUVEAU,<sup>1,10,12</sup>  AND MARLENE WIART<sup>3,10,12,\*</sup> 

<sup>1</sup>Univ-Lyon, Lyon Neuroscience Research Center, CNRS UMR5292, Inserm U1028, Université Claude Bernard Lyon 1, Lyon, France

<sup>2</sup>Univ-Clermont Auvergne; CNRS; SIGMA Clermont; Institut Pascal, Clermont-Ferrand, France

<sup>3</sup>Univ-Lyon, CarMeN laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Charles Mérieux Medical School, F-69600, Oullins, France

<sup>4</sup>Univ-Lyon, Hospices Civils de Lyon, Lyon, France

<sup>5</sup>Univ-Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France

<sup>6</sup>NOVITOM, Grenoble, France

<sup>7</sup>Univ-Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, Inserm, CREATIS UMR5220, U1206, F-69621, France

<sup>8</sup>Cermep, Lyon, France

<sup>9</sup>Université Grenoble Alpes, Inserm UA7 Strobe, Grenoble, France

<sup>10</sup>CNRS, Lyon, France

<sup>11</sup>Co-first authors

<sup>12</sup>Co-last authors

\*marlene.wiart@univ-lyon1.fr

**Abstract:** White-matter injury leads to severe functional loss in many neurological diseases. Myelin staining on histological samples is the most common technique to investigate white-matter fibers. However, tissue processing and sectioning may affect the reliability of 3D volumetric assessments. The purpose of this study was to propose an approach that enables myelin fibers to be mapped in the whole rodent brain with microscopic resolution and without the need for strenuous staining. With this aim, we coupled in-line (propagation-based) X-ray phase-contrast tomography (XPCT) to ethanol-induced brain sample dehydration. We here provide the proof-of-concept that this approach enhances myelinated axons in rodent and human brain tissue. In addition, we demonstrated that white-matter injuries could be detected and quantified with this approach, using three animal models: ischemic stroke, premature birth and multiple sclerosis. Furthermore, in analogy to diffusion tensor imaging (DTI), we retrieved fiber directions and DTI-like diffusion metrics from our XPCT data to quantitatively characterize white-matter microstructure. Finally, we showed that this non-destructive approach was compatible with subsequent complementary brain sample analysis by conventional histology. In-line XPCT might thus become a novel gold-standard for investigating white-matter injury in the intact brain. This is Part I of a series of two articles reporting the value of in-line XPCT for virtual histology of the brain; Part II shows how in-line XPCT enables the whole-brain 3D morphometric analysis of amyloid- $\beta$  (A $\beta$ ) plaques.

## 1. Introduction

White-matter injury leads to severe functional loss in many neurological diseases. Diagnosis and monitoring of white-matter damage and repair is therefore paramount in order to limit the handicap resulting from these conditions. Magnetic resonance imaging techniques such as diffusion tensor imaging (DTI) and its variants (q-balls, kurtosis imaging) are now instrumental for the assessment of white-matter abnormalities [1]. Beside displaying fiber tract orientation maps, these approaches provide quantitative metrics such as fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD), which in combination serve as biomarkers of axonal and myelin damage [2]. However, these techniques still present limitations, notably due to partial volume effects, the difficulty of resolving crossed fibers, and the delicate interpretation of DTI metrics that may be influenced by factors other than axonal degeneration and myelin degradation, such as inflammation and astrogliosis [3]. In addition, for post-mortem samples, acquisition times are very long (several hours to days) to achieve spatial resolution in the 10  $\mu\text{m}$  – 100  $\mu\text{m}$  range, thus preventing high-throughput imaging of high-resolution 3D datasets. There is thus a crucial need to develop novel whole-brain imaging approaches to study white-matter tracts at the microscopic level [4], especially for the investigation of animal models of white-matter injury.

Myelin staining on histological samples is a fundamental technique employed in many areas of neuroscience to study white-matter fibers. However, tissue processing and sectioning affect the reliability of 3-dimensional (3D) volumetric assessments. Recently, brain-clearing approaches coupled to the use of antibodies, for example targeting myelin basic protein (MBP) to visualize myelinated axons [5], have been proposed to overcome these limitations. Unfortunately, these techniques are laborious and time-consuming. In addition, tissue immunostaining is dependent on antibody penetration into the optically cleared brain, while light-sheet microscopy (the companion imaging tool for imaging cleared tissues) has limited through-plane resolution, thus introducing bias when retrieving 3D information [6].

X-ray based virtual histology is emerging as a new discipline, virtually slicing 3D datasets in any direction at microscopic level [7]. X-ray phase-contrast tomography (XPCT) using synchrotron radiation is particularly promising to image microstructures in excised biological tissues that have weak X-ray absorption. XPCT achieves a high signal-to-noise ratio without the need to add staining agents. It offers micrometric spatial resolution and isotropic reconstruction in a 1  $\text{cm}^3$  field of view (FOV), thus providing the ideal prerequisites for imaging white-matter fibers in the entire and intact (unsliced, unstained) rodent brain. To meet this challenge, however, certain improvements are required, notably to obtain sufficient contrast-to-noise in axons without labor-intensive contrast-enhancing steps [8].

We previously developed an imaging technique relying on in-line XPCT that identifies mouse brain anatomy as clearly as histology, with acquisition time in the range of minutes [9–11]. We here propose an optimized approach to map myelin fibers in the whole mouse brain with microscopic resolution without the need for strenuous staining. We provide the proof-of-concept that this approach enhances myelinated fibers in rodent and human brain tissue. In addition, we demonstrated that the technique detected and quantified white-matter injuries using three animal models: ischemic stroke, premature birth and multiple sclerosis. Furthermore, analogously to diffusion tensor imaging (DTI), we retrieved fiber directions and DTI-like diffusion metrics from our XPCT data to quantitatively characterize white-matter microstructures. Finally, we here show that this non-destructive approach is compatible with subsequent complementary brain sample analysis by conventional histology. In-line XPCT might thus become a novel gold-standard for investigating white-matter injury in the intact brain *ex vivo*. This is Part I of a series of two articles reporting the value of in-line XPCT for virtual histology of the brain; Part II shows how in-line XPCT enables whole-brain 3D morphometric analysis of amyloid- $\beta$  ( $A\beta$ ) plaques [12].

## 2. Materials and methods

Table 1 summarizes the samples and imaging techniques used in the study.

**Table 1. Summary of 19 samples used for XPCT, with concurrent testing of different ethanol titrations for sample preparation, DTI, histology and CLARITY evaluations.**

| Species | Age      | Disease / Animal model  | XPCT | DTI | Histology | CLARITY | Ethanol gradient |
|---------|----------|-------------------------|------|-----|-----------|---------|------------------|
|         |          | None                    | 8    | 1   | 1         | 1       | 5                |
|         | 8 weeks  | Ischemic stroke         | 2    |     | 1         |         |                  |
| Mouse   |          | Multiple sclerosis      | 2    |     |           |         |                  |
|         | 11 days  | Premature birth         |      |     |           |         |                  |
|         |          | <i>Normoxia</i>         | 2    |     | 2         |         |                  |
|         |          | <i>Hypoxia</i>          | 2    |     | 2         |         |                  |
| Rat     | 10 weeks | Multiple sclerosis      | 1    | 1   |           |         |                  |
| Human   | 70 y.o.  | Frontotemporal dementia | 2    |     |           | 1       |                  |

### 2.1. Animals

All experimental procedures involving animals and their care were carried out in accordance with European regulations for animal use (EEC Council Directive 2010/63/EU, OJ L 276, Oct. 20, 2010). The study was approved by our local review board "Comité d'éthique pour l'Expérimentation Animale Neurosciences Lyon" (CELYNE - CNREEA number: C2EA – 42, APAFIS#7457-2016110414498389, 5892-2016063014207327, 187-2015011615386357). Sixteen rodents (Janvier, France) were used (Table 1). Animals were housed in a temperature- and humidity-controlled environment ( $21 \pm 3^\circ\text{C}$ ), with 12 : 12 h light-dark cycle, with free access to standard chow and tap water. For surgeries, animals were anesthetized with isoflurane (induction: 3.5 %; surgery: 2 %; ISO-VET, Piramal Healthcare, Morpeth, UK). Pain was alleviated by subcutaneous injection of buprenorphine at 0.05 mg/kg prior to surgery. During surgery, body temperature was monitored with a rectal probe and maintained at  $37^\circ\text{C}$  using a feedback-regulated heating pad. At end of surgery, wounds were treated with lidocaine (lidocaine/prilocaine 5 %, Pierre Fabre, France).

### 2.2. Animal models of white-matter injury

Three animal models of white-matter injury that lead to myelin damage were used; the number of animals per model is specified in Table 1. Firstly, focal cerebral ischemia, a model of ischemic stroke encompassing the sensorimotor cortex and adjacent corpus callosum, was induced by permanent occlusion of the distal middle cerebral artery (pMCAO), as previously described [13]. Briefly, the right MCA was exposed by subtemporal craniectomy and occluded by electrocoagulating the distal part for 10 minutes. The animals were then allowed to recover from anesthesia and sacrificed at day 9 post-surgery. Secondly, chronic hypoxia was used as a model of very premature birth. This model consists in placing newborn mice in chronic hypoxia —10 %  $\text{O}_2$  for 8 days— during the early postnatal period —from post-natal day #3 (P3) to post-natal

day #11 (P11)—, corresponding to the late prenatal period of brain development in humans. This model reproduces all histopathological features observed in very preterm infants, including diffuse white-matter injuries [14]. Mice were sacrificed at the end of the hypoxic period: i.e., P11. Thirdly, focal demyelinating lesions, a model of multiple sclerosis, were induced by stereotaxic injection of lysophosphatidylcholine (LPC) (Sigma-Aldrich, ref. L4129) at 1 % in saline solution into the corpus callosum as previously described [15,16]. After bilateral craniotomy, LPC and saline were slowly infused (0.1  $\mu\text{L}/\text{min}$ ) with 30-gauge needles via tubing connected to syringes installed in injection pumps. In one mouse, 1- $\mu\text{L}$  was injected at AP 0.0 mm; ML  $\pm 2.5$  mm; DV -2.0 mm, with contralateral injection of 1  $\mu\text{L}$  saline. In the other mouse, 2  $\mu\text{L}$  was injected at the same ipsilateral site, without contralateral injection. In the rat, 5  $\mu\text{L}$  was injected: AP -0.3 mm; ML  $\pm 3.3$  mm; DV -2.8 mm / -3.5 mm; 2.5  $\mu\text{L}$  each, from depth to superficial, with contralateral injection of 5  $\mu\text{L}$  saline. The animals were then allowed to recover from anesthesia and sacrificed at day 7–9 post-surgery.

### 2.3. *In vivo MRI*

For *in vivo* MRI, the animals were placed in a temperature-controlled cradle and anesthetized by isoflurane as for surgery. The respiratory rhythm was monitored by a pressure sensor linked to a monitoring system (ECG Trigger Unit HR V2.0, RAPID Biomedical, Rimpar, Germany). MRI was performed on a horizontal 7 T Bruker BioSpec MRI system (Bruker Biospin MRI GmbH, Bruker, Germany) equipped with a set of gradients of 440mT/m and controlled via a Bruker ParaVision 5.1 workstation. A Bruker birdcage volume coil (inner diameter = 72 mm, outer diameter = 112 mm) was used for transmission, and a Bruker single loop surface coil (15 mm diameter) was used for reception. T2-weighted imaging and DTI were obtained; Table S1 summarizes the acquisition parameters.

### 2.4. *Rodent and human brain sample preparation*

All animals were euthanized by intracardiac perfusion with phosphate-buffered saline (PBS) and their brains were harvested. For XPCT, the impact of dehydration was examined in healthy brains fixed by formaldehyde 4 % and dehydrated in ethanol baths (25 %; 50 %; 75 % and 96 %). All subsequent (rodent and human) brains were fixed in formaldehyde 4 % and then dehydrated in successive ethanol baths until a titration of 96 % was reached. The total time for sample preparation was below 30 minutes. Some of the mouse brains were re-hydrated for histology and immunohistology. In addition to the rodent brains, cortex tissue (2 adjacent blocks of approx. 1  $\text{cm}^3$ ) from one patient with frontotemporal dementia was imaged; it was obtained from the local brain bank in Lyon: Tissue Tumorotheque Est, CRB-HCL (national authorizations DC2008-72 & AC2015-2576). One healthy mouse and one human brain sample were cleared with the CLARITY system to achieve brain clearing [17] after formaldehyde fixation and before ethanol dehydration: brains were incubated in a polymerization solution composed of PBS buffer 1X, with the addition of VA-044 concentrated at 0.25 % and acrylamide 4 %. Brains were kept in the solution for 12 hours at 4°C. After infusion, the gel was polymerized at 37°C under gentle agitation for 3 hours. Brains were then placed in the Logos electrophoretic tissue clearing solution for one day and cleared using the electrophoretic chamber of the X-Clarity system. Brains were cleared at 1.5 A in 6 (mouse) or 8 (human) hours. The total time for sample clearing was 2 days.

### 2.5. *X-ray phase-contrast computed tomography (XPCT)*

Imaging was performed at the ID17 and ID19 beamlines of the ESRF, the European Synchrotron (ESRF, Grenoble, France). The samples (whole mouse brains, rat hemispheres) were conditioned in 1 cm diameter plastic tubes filled with ethanol 96 %. We used the propagation-based imaging technique, which exploits free-space propagation in order to have detectable interference fringes. An example of the experimental set-up is shown in Fig. S1. A summary of experimental and

reconstruction parameters is given in Table S2. Briefly, the tomographic images were recorded at a single sample-detector distance where the camera was positioned away from the sample to obtain phase contrast. The experiments were performed with a "pink" incident X-ray beam generated by the undulator on ID19 (energy: 19 keV–35 keV according to the experiment setting, Table S2). When the sample exceeded the beam size in Z-direction, two stacks were acquired with  $\sim 100$  slices overlap and stitched afterwards. Tomographic reconstructions were performed after using the Paganin single distance phase-retrieval approach of the PyHST2 software using standard unsharp masking [18]. For all scans, the  $\delta/\beta$  ratio was set in the range [600;1000] on an image-to-image basis depending on the brain structures present in the image, in order to provide optimal contrast without blurring the image too much [10,11] (Table S2). Of note, in a preliminary work, we have already shown that fiber detectability reached a plateau in this range [11].

## 2.6. Data processing and quantitative analysis

The mouse brain library was used for labeling white-matter fiber tracks (<http://www.mbl.org/mbl.main/atlas.html>). Maximum intensity projections were generated using ImageJ software (<https://imagej.nih.gov/ij/index.html>). Segmentation, analysis and volume rendering were performed with Amira Software (<https://thermofisher.com/amira-avizo>). For fiber density quantification, XPCT hyperintense signals of the caudate putamen were segmented using a home-made pipeline made with Amira Software. This pipeline relied on a structure-enhancement filter (Frangi filter for rod-like elements [19]), then processed with the TEASAR tree-structure extraction algorithm [20] to segment the white-matter network. Fiber density was then evaluated as the ratio of the number of segmented voxels over the total number of voxels within 3D ROIs. For mice with pMCAO, ROIs encompassing 100 axial slices at the level of the ischemic lesion were placed in the peri-lesional caudate putamen. For mice with chronic hypoxia, ROIs encompassing 60 slices were placed in the center of the caudate putamen. The DTI parametric maps (FA, RD, AD) were reconstructed from MRI data using DSI studio software (<http://dsi-studio.labsolver.org>). The DTI-like parametric maps were computed from XPCT images using a dedicated tool developed by NOVITOM (<https://www.novitom.com/en/>) specifically for the current study. The algorithm was developed based on image gradient analysis to detect fibers orientation. The basic idea is that image gradient should be minimal along the fibers direction. The first step is the computation of the image intensity gradient along the 3 spatial axes, giving a gradient vector for each voxel:

$$\vec{\nabla}I = \begin{pmatrix} \frac{\partial I}{\partial x} \\ \frac{\partial I}{\partial y} \\ \frac{\partial I}{\partial z} \end{pmatrix} = \begin{pmatrix} g_x \\ g_y \\ g_z \end{pmatrix} \quad (1)$$

The gradient orientation tensor (or covariance matrix) is then built using the tensor product:

$$T_g = \vec{\nabla}I \otimes \vec{\nabla}I = \begin{pmatrix} g_x g_x & g_x g_y & g_x g_z \\ g_y g_x & g_y g_y & g_y g_z \\ g_z g_x & g_z g_y & g_z g_z \end{pmatrix} \quad (2)$$

The tensor components are locally correlated using a convolution by a Gaussian kernel  $k_g$  with a standard deviation  $\sigma_g$ :

$$(T_g * k_g)(x, y) = \int_u \int_v T_g(u, v) \frac{1}{\sigma_g \sqrt{2\pi}} \exp\left(-\frac{(x-u)^2 + (y-v)^2}{2\sigma_g^2}\right) du dv \quad (3)$$

Then the gradient orientation tensor is diagonalized to extract the local orientation axes:

$$D^{-1}T_gD = \begin{pmatrix} \eta_1 & 0 & 0 \\ 0 & \eta_2 & 0 \\ 0 & 0 & \eta_3 \end{pmatrix}, \text{ with } D = (\vec{a}_1 \vec{a}_2 \vec{a}_3) \quad (4)$$

The eigen vectors  $\vec{a}_i$  ( $i \in [1; 3]$ ) are associated with the eigen values  $\eta_i$ . The eigen vector  $\vec{a}_n$  associated with the smallest eigen value is aligned with the direction in which the gradient is weakest, which should be locally aligned with the fiber direction. The fiber orientation  $\vec{v}_f$  is defined as:

$$\vec{v}_f = \frac{\vec{a}_n}{\|\vec{a}_n\|} \quad (5)$$

The fiber orientation tensor is constructed as the tensor product of this vector by itself:

$$T_f = \vec{v}_f \otimes \vec{v}_f \quad (6)$$

The components of the tensor are locally correlated by applying a convolution by a Gaussian kernel  $k_f$  with a standard deviation  $\sigma_f$ :

$$(T_f * k_f)(x, y) = \int_u \int_v T_f(u, v) \frac{1}{\sigma_f \sqrt{2\pi}} \exp\left(-\frac{(x-u)^2 + (y-v)^2}{2\sigma_f^2}\right) du dv \quad (7)$$

Finally, the fiber orientation tensor is diagonalized to obtain the eigenvalues  $\lambda_j$  ( $j \in [1; 3]$ ), used to compute the DTI parametric maps:

$$AD = \lambda_1 \quad (8a)$$

$$RD = \frac{\lambda_2 + \lambda_3}{2} \quad (8b)$$

$$FA = \sqrt{\frac{3}{2} \frac{\sqrt{(\lambda_1 - \bar{\lambda})^2 + (\lambda_2 - \bar{\lambda})^2 + (\lambda_3 - \bar{\lambda})^2}}{\lambda_1^2 + \lambda_2^2 + \lambda_3^2}} \quad \text{where } \bar{\lambda} = \frac{\lambda_1 + \lambda_2 + \lambda_3}{3} \quad (8c)$$

## 2.7. Histology and immunohistology

Brain samples were frozen at  $-80^\circ\text{C}$ . For GFAP and collagen IV staining, rehydrated frozen brains were cut into  $12 \mu\text{m}$  axial sections using a cryostat. Brain slices were rehydrated 10 minutes in 0.1 M PBS, fixed for 20 minutes in 4 % PFA, and rinsed 3 times with PBS. They were then blocked and permeabilized in PBS (Sigma-Aldrich, Saint Louis, MO, USA) with 5 % BSA (bovine serum albumin, Sigma-Aldrich, Saint Louis, MO, USA) and 0.5 % Triton X-100 (PBST) for 30 minutes at room temperature. Slides were then incubated overnight at  $4^\circ\text{C}$  with primary polyclonal anti-GFAP rabbit antibody (1:1000; Z0334, DAKO, Golstrup, Denmark) or anti-collagen IV rabbit antibody (1:200, AB6586, AbCam, Cambridge, UK) dissolved in 0.5 % PBST. They were then washed 3 times in PBS and incubated with a secondary anti-rabbit GFP antibody dissolved in PBST (1:1000, AF546, ThermoFisher, Waltham, MA, USA) for 1 hour at room temperature. Finally, slides were rinsed 3 times in PBS and mounted in aqueous medium containing DAPI (Roti-Mount, Carl Roth, Karlsruhe, Germany). For Sudan Black B staining, brain slices were post-fixed with 4 % formaldehyde in PBS, briefly dehydrated in 70 % ethanol and then incubated in 0.1 % Sudan Black B solution (Sigma-Aldrich, ref. 199664, Saint Louis, MO, USA) at room temperature for 10 minutes. They were then washed in 70 % ethanol for 10–30 minutes and moved into distilled water to be mounted in aqueous medium

(Roti-Mount, Carl Roth, Karlsruhe, Germany). For MBP staining, brains were first rehydrated in 0.1 M PBS, then cut into 50  $\mu\text{m}$  axial sections using a vibratome. Free-floating sections were blocked in TNB buffer (0.1 M PB; 0.5 % Casein; 0.25 % BSA; 0.25 % TopBlock) with 0.4 % triton-X (TNB-Tx), then incubated overnight at 4°C with a rabbit anti-MBP primary antibody (1:1000; AbCam, Cambridge, UK), under constant gentle shaking. Following extensive washing in 0.1 M PBS with 4°C triton-X (PB-Tx), sections were incubated with appropriate secondary antibodies conjugated with Alexafluor 488 (1:500; Life Technologies, Carlsbad, Germany) for 4 hours at room temperature. Sections were washed and counterstained with DAPI (300 nM; D1306; Life Technologies, Carlsbad, Germany). Images were acquired using an Axio Scope A.1 fluorescence microscope (4 filters, Carl Zeiss, Oberkochen, Germany) equipped with a  $\times 0.63$  AxioCam MRc (Carl Zeiss, Oberkochen, Germany).


### 2.8. Data and code availability statement

The XPCT raw data cannot be shared at this time due to the large size of the datasets, but can be made available on reasonable request. The DTI-like algorithm is the property of NOVITOM.

## 3. Results

### 3.1. XPCT enables visualization of myelinated white-matter fibers in the whole mouse brain

We first aimed to evaluate the impact of dehydration on XPCT brain contrast. As reported earlier by ourselves and others [9,21–24], formaldehyde fixation resulted in faint hypointense contrast of white-matter fiber tracts (Fig. 1, 0 %). Successive baths of ethanol resulted in appearance of hyperintense signal in myelinated white-matter fibers, with dose effect (Fig. 1, 25%–96%). Because ethanol 96 % dehydration produced the best visual contrast, we adopted this brain processing technique for the rest of the study. XPCT of dehydrated brain samples provided 3D mapping of all myelinated white-matter tracts, enabling accurate labeling despite tissue shrinkage (Fig. 2). Dynamic visualization of virtual slicing ([Visualization 1](#) for coronal incidence and [Visualization 2](#) for sagittal incidence) and static visualization of maximum intensity projections (Fig. 2(C-D-E-H-I)) revealed the complexity of fiber orientations and entanglement in the whole brain (see for example stria medullaris and fasciculus retroflexus in Fig. 2(E)).




**Fig. 1.** Ethanol dehydration enhances myelin contrast on images obtained with in-line XPCT. Axial section (Bregma 0) through brains prepared using PFA 4 % and a gradient of ethanol baths [25%–96%].


Importantly, XPCT contrast enhancement of white matter was also observed in human brain tissue after dehydration (Fig. 3(A), arrows).

Brain anatomy was exquisitely revealed by XPCT, with many relevant neurological features (overall vasculature, neuronal bodies of the barrel cortex and hippocampus layers, choroid plexus, cerebellum, etc.) being clearly identifiable (Fig. S5).





**Fig. 2.** White matter fiber tracts are revealed by XPCT in a mouse brain. The same brain sample is shown in all panels from a mouse with LPC administration with a focus on normal-appearing white matter. (A) Sagittal view of single slice; (B) Corresponding axial view of single slice; (C) Maximum intensity projection (MIP) of sagittal view over 35 slices (262  $\mu\text{m}$ ), with white matter fiber tracts annotations; (D) MIP showing the entanglement between stria medullaris (sm) and the posterior commissure (pc); (E) MIP showing the entanglement between stria medullaris (sm) and the fornix (fr); (F) Sagittal view of single slice; (G) Corresponding coronal view; (H) Maximum intensity projection (MIP) of sagittal view over 35 slices (750  $\mu\text{m}$ ), with white matter fiber tract annotations; (I) MIP of coronal view over 35 slices (750  $\mu\text{m}$ ), with white matter fiber tract annotations; Labels: aco anterior commissure, olfactory limb; act anterior commissure, temporal limb; cc corpus callosum; cg cingulum; cpd cerebral peduncle; CPu caudate putamen; df dorsal fornix; fi fimbria; fr fasciculus retroflexus; fx columns of the fornix; mtt mammillothalamic tract; sm stria medullaris; st stria terminalis; opt optical tract; pc posterior commissure.; vhc ventral hippocampal commissure.



**Fig. 3.** White matter fiber tracts are revealed by XPCT in a human brain and disappear upon demyelination brain clearing. **(A-B)** Single XPCT slice of a human brain sample from 2 distinct but adjacent blocks. **(A)** Ethanol dehydration reveals white matter as hyperintense areas (arrows); **(B)** White matter hyperintense signal is lost after demyelination by brain clearing. Other anatomical landmarks such as large vessels are clearly seen (large blue arrowheads). Because the sample was not perfused, there is also contrast from small vessels (smaller green arrowheads); **(C-D)** Single XPCT slice through a rodent brain **(C)** without and **(D)** with demyelination by brain clearing: note the disappearance of white matter hyperintense signal. Clearing procedure induced brain expansion and ethanol dehydration induced brain shrinkage, hence the slight difference in sample size.

### 3.2. XPCT white-matter enhancement in dehydrated brain samples is related to myelin

We hypothesized that the white-matter contrast seen with our approach was related to a mismatch of refractive indices between myelin and surrounding tissue, occurring after the removal of water by ethanol. Myelin has a much higher lipid content than gray matter [25] and might thus be less affected by dehydration than other brain tissues. To investigate this possibility, we used brain clearing, a technique that removes lipids (and hence the myelin sheath) to render the brain translucent to light before ethanol dehydration [26–28]. We observed a loss of white-matter tract contrast after lipid removal in both human (Fig. 3(B)) and mouse brains (Fig. 3(D)), suggesting a role of myelin in contrast generation.

### 3.3. XPCT detects and quantifies white-matter injuries in a range of animal models

We then aimed to evaluate the value of XPCT as a virtual histology tool for the diagnosis and characterization of white-matter injuries. For this, we used 3 different small animal models:

1. ischemic stroke (pMCAO),
2. premature birth (neonatal chronic hypoxia) and
3. multiple sclerosis (intracerebral LPC administration).

Firstly, the pMCAO model induced a focal lesion in the sensorimotor cortex, as seen on the in vivo ADC map (Fig. 4(A), white dotted lines) and T2-weighted MRI (Fig. 4(B), white dotted lines). Subcortical white-matter loss, as can be seen in Fig. 4(C) (yellow dashed lines), may occur

in this model; it is not detectable on conventional MRI and difficult to quantify on histology; with XPCT, 3D segmentation of white matter in the caudate putamen and subsequent quantification of fiber density enabled white-matter loss to be assessed in one individual (Fig. 4(D)) and white-matter integrity in the other (Table 2).

**Table 2. XPCT quantifications (ROI: region of interest; SD: standard deviation)**


| Animal model       | Parameter  |                                |             |                              |
|--------------------|--|--------------------------------|-------------|------------------------------|
| Ischemic stroke    | <b>Fiber density (%)</b>   |                                |             |                              |
|                    | Mouse #1   |                                | Mouse #2    |                              |
|                    | Ipsilateral  | Contralateral                  | Ipsilateral | Contralateral                |
|                    | 6%   | 11%                            | 11%         | 13%                          |
| Premature birth    | <b>Fiber density, mean of left and right ROI <math>\pm</math> SD</b> |                                |             |                              |
| <i>Normoxia</i>    | Mouse #3   |                                | Mouse #4    |                              |
|                    | 11% $\pm$ 2%   |                                | 9% $\pm$ 2% |                              |
| <i>Hypoxia</i>     | Mouse #5   |                                | Mouse #6    |                              |
|                    | 0% $\pm$ 0%  |                                | 0% $\pm$ 2% |                              |
| Multiple sclerosis | <b>Lesion volumes (<math>10^8 \times \mu\text{m}^3</math>)</b>       |                                |             |                              |
|                    | Mouse #7 (2 $\mu\text{L}$ LPC)                                       | Mouse #8 (1 $\mu\text{L}$ LPC) |             | Rat #1 (5 $\mu\text{L}$ LPC) |
|                    | 4.4  | 1.2 & 1.8                      |             | 8.7                          |
|                    | <b>DTI-like parameters (% of mirror ROI)</b>                         |                                |             |                              |
|                    | Rat #1 (5 $\mu\text{L}$ LPC)   |                                |             |                              |
|                    | FA: 72%  | AD: 79%                        |             | RD: 146%                     |

Secondly, normoxic mouse neonates showed normal white matter aspect (Fig. 4(E)) while their hypoxic littermates exhibited very faint white-matter contrast (Fig. 4(F)). This difference in white-matter content was quantified in the striatum on an individual basis (Table 2).


Thirdly, areas of focal demyelination were clearly observed in LPC-injected animals (Fig. 5(A-B), arrow: internal capsule and caudate putamen). Focal lesions remote from the injection site were also seen in one animal, including collapse of the ipsilateral lateral ventricle (Fig. 5(A), arrowhead) and demyelination of the olfactory limb of the anterior commissure (Fig. 5(C), arrowhead). Disorganization of the stria terminalis was also observed in this mouse, despite the very small size of this fiber tract (Fig. 5(D), dashed lines). Segmentation of white-matter abnormalities gave ready access to the volume of demyelinated areas in the individual animals (Fig. 5(E), Table 2).

### 3.4. Fiber directions and diffusion metrics can be retrieved from XPCT data

To go further in the analysis of XPCT data, we explored reconstructing the orientation of brain fibers to shed light on brain structural connectivity. A DTI-like algorithm was developed, based on digital gradient analysis to detect fiber orientation [29]. Some of the brain samples (1 normal




**Fig. 4.** XPCT identifies subcortical white matter loss in mouse models of ischemic stroke and preterm birth. (A-D) MRI and XPCT data in a mouse model of ischemic stroke (mouse #1 of Table 2). (A) In vivo MRI data of mouse brain with pMCAO (single slice with 800  $\mu\text{m}$  thickness) imaged at 6 hours post-ischemia. The ischemic lesion (white dotted line) appears hypointense on apparent diffusion coefficient map (A) and hyperintense on T2-weighted image (B); (C) MIP over 107 slices (807  $\mu\text{m}$ ) of XPCT data obtained at the same slice level in the same mouse after sacrifice at day 9 post-ischemia. At this stage, the infarcted cortex tended to come off along the perfusion, extraction and dehydration steps of the brain. White matter loss is clearly seen in the subcortical peri-lesional area in this animal (yellow dashed line); (D) Segmentation of caudate putamen white-matter fibers and quantification of fiber density in symmetrical regions (percentage calculated in 3D ROIs over 100 slices). The background XPCT native image is represented in false colors to provide a cresyl violet-like contrast using a home-made colormap. (E-F) XPCT data in a mouse model of preterm birth: native (single axial slice) XPCT images in (E) normoxic and (F) hypoxic mice at post-natal day #11. White-matter fiber tracts were segmented and quantified in the striatum as shown in blue in normoxic animal (mouse #3 of Table 2) (E) but barely detectable in the animals that underwent neonatal chronic hypoxia (mouse #5 of Table 2) (F).



**Fig. 5.** XPCT detects white-matter fiber tract damage in a mouse model of focal demyelination. **(A)** MIP of axial views over 100 slices (750  $\mu\text{m}$ ) at the level of the lateral ventricles. Focal demyelination is clearly seen in the internal capsule (arrow). Other focal lesions are shown in the ipsilateral (right) side with an arrow head such as lateral ventricle collapse; **(B)** MIP of sagittal views at the level of the lateral ventricle over 100 slices (750  $\mu\text{m}$ ); Again, focal demyelination is clearly seen in the internal capsule (arrow); **(C)** MIP of axial views over 100 slices (750  $\mu\text{m}$ ) at the level of the anterior commissure; degeneration of white-matter fiber tracts can be seen in the ipsilateral anterior part of the anterior commissure (arrowhead); **(D)** Disorganization of the ipsilateral stria terminalis is also seen compared to the contralateral stria, despite the small size of this fiber tract (dashed lines). **(E-F)** Segmentation and quantification of lesion volumes in two separate mice where demyelinated lesions were induced with the LPC model.

mouse, and 1 LPC-injected rat) were imaged back-to-back with in vivo DTI (Table 1). Visual examination of brain-wide connectivity maps showed good agreement between the 2 techniques (Fig. 6(A-C)). LPC-induced demyelination of the corpus callosum was clearly depicted on XPCT fiber-orientation maps (Fig. 6(D-E)), whereas on DTI maps it was less clear (Fig. 6(F)). Fig. 6(G-H) shows examples of diffusion metrics maps obtained with in vivo DTI and XPCT respectively in the same animal. Examples of direction maps obtained in ischemic stroke and hypoxia is shown in Fig. S4. To compare FA values in the same regions of interest we have




**Fig. 6.** XPCT retrieves brain-wide structural connectivity in a DTI-like manner. (A) MIP over 5 slices ( $37.5 \mu\text{m}$ ) of a healthy mouse brain (coronal view); (B) Color-coded direction map extracted from XPCT from the same data set (cf. Fig. S3); (C) Color-coded direction map from in vivo DTI obtained in the same mouse at the corresponding slice level. White-matter tract directions are identical between the two techniques within major white-matter tracts such as corpus callosum (cc), fornix (fx), anterior commissure (ac) and caudate putamen (CPu); (D) MIP over 10 slices ( $65 \mu\text{m}$ ) of a rat brain with an LPC-induced lesion in the corpus callosum (coronal view, arrowhead); (E) Color-coded direction map extracted from XPCT from the same dataset. The loss in right-left directionality is clearly seen in the demyelinated area compared to the contralateral side (inserts); (F) Color-coded direction map from in vivo DTI obtained in the same rat at the corresponding slice level; (G) Native DTI data ( $b_0$ ) for a rat with an LPC lesion (coronal view). The box indicates DTI slice thickness ( $1000 \mu\text{m}$ ) and the arrow points to the area of demyelination. DTI metrics maps of this slice are shown in axial incidence. (H) MIP over 5 slices ( $65 \mu\text{m}$ ) of XPCT image and DTI-like metrics maps corresponding to the slice indicated on the MIP (slice thickness:  $6.5 \mu\text{m}$ ).

registered the DTI volume with affine transformation over the XPCT volume and oversampled to the XPCT voxel size with nearest neighbor interpolation. The mean FA value was compared in 16 regions sampled in major white matter fiber tracts. There was a fair correlation between the two approaches (Fig. S2).

Quantification of these metrics in the injured corpus callosum further confirmed the ability of XPCT to quantitatively assess microstructural white-matter abnormalities, with a marked increase in DTI-like RD and a smaller decrease in DTI-like FA and AD compared to the symmetrically contralateral region (Table 2), as expected in demyelinated areas with limited axonal damage [2].

### 3.5. XPCT is compatible with subsequent conventional histology of brain samples

Finally, we aimed to ascertain that brain imaging with XPCT did not prevent complementary analysis with on standard approaches such as histological staining and immunohistochemistry. After XPCT imaging, 3 brain samples were rehydrated and processed using our conventional 2D histology protocols. GFAP (Fig. 7(A)), collagen type IV (Fig. 7(B)), Sudan Black B (Fig. 7(C)) and myelin basic protein (MBP) (Fig. 7(D)) immunostaining was readily achievable, with no noticeable impact of prior processing and imaging on staining quality.



**Fig. 7.** Brain preparation for XPCT does not prevent further brain evaluation with immunohistochemistry. (A) Constitutive expression of astrocytes GFAP in healthy mouse (CC: corpus callosum, LV: lateral ventricle); (B) Collagen IV overexpression in the ischemic lesion of a pMCAO mouse; (C) Sudan Black B staining (myelin marker) of a pMCAO mouse with demyelination of the corpus callosum (blue arrow) and (D) Myelin basic protein (MBP) staining in neonatal mice (P11); three slice levels are shown.

#### 4. Discussion

This paper describes a novel label-free method based on in-line XPCT for mapping myelin in the whole mouse brain. XPCT offers many advantages over other intact-brain approaches such as electron microscopy [30,31], brain clearing [5], small angle X-ray scattering (SAXS) CT [6,32,33] or dark field CT [34]. Firstly, the FOV-to-resolution ratio is optimal for imaging the whole rodent brain at microscopic level. Secondly, isotropic resolution enables straightforward analysis of the 3D imaging data. Thirdly, acquisition and reconstruction times remain within a range of minutes. And last but not least, phase sensitivity offers an alternative to staining, as contrast between tissues is based on changes in X-ray phase rather than on absorption. Consequently, sample preparation is simple and fast. Taken together, this should enable high-throughput whole-brain studies in small laboratory animals and 3D evaluation of human brain samples.

However, phase contrast alone is not sufficient to enhance white-matter tracts, probably because the differences in refractive index between axons and surrounding tissue are minimal. The originality of our approach was to obtain myelin specificity simply by modulating the refractive indices through dehydration of brain samples with ethanol. Ethanol dehydration is the first step before paraffin embedment for histological analysis and is therefore a way of preparing brain samples that is already well-accepted by the neuroscientific community. Ethanol fixation has already been used for virtual XPCT histology of whole organs: vocal folds [35], lung [36], heart [36,37], and kidney [36,38,39]. A few brain studies also mentioned using ethanol dehydration to prepare their sample; however, they focused on displaying the angio- and/or cyto-architecture of the brain, or neuropathological features such as amyloid plaques, and did not report specific enhancement of myelinated axons [22,23,40–43]. Therefore, to the best of our knowledge, we are the first to specifically investigate and demonstrate the value of combining in-line XPCT with ethanol dehydration for 3D visualization of white-matter fiber tracts in the whole mouse brain, to relate the enhanced signal to myelin, and to provide a comprehensive framework for applications in neurological diseases.

Beside its well-known vital role in conducting signals along the nerves, myelin has many other indispensable functions in the central nervous system: providing metabolic support to axons, regulating ion and water homeostasis, and finely tuning neuronal signaling [44]. Consequently, disruption of myelin has significant neurological impact. Investigation of myelin disruption and loss in animal models is relevant not only for pathophysiology but also for lesion repair and drug discovery. We here showed, in three different animal models, that XPCT is a powerful tool to probe white-matter injury at organ scale. 3D regions of myelin loss were accurately quantified, and lesions remote from the primary injury site were straightforwardly identified. These intact-brain analyses are a major improvement over classical histology, which involves slicing the brain tissue: i.e., disrupting the structural integrity of axonal tracts.

The technique of directional diffusion is widely used to study white-matter microstructural connections [45]. However, DTI has limited in-plane and through-plane spatial resolution, and provides indirect observation of white-matter fibers. Moreover, even when performed *ex vivo* at high resolution, partial volume effects may impair DTI metrics accuracy, and the very long scanning time (typically overnight) is prone to vibration artefacts and tissue heating. We here show that XPCT can be used to obtain an estimate of whole-brain axonal tract orientations in microscopic voxels. This information can then be combined with a directional algorithm to reconstruct structural connections. Classical diffusion metrics (fractional anisotropy, axial, and radial diffusivities) can also be extracted from the diffusion tensor obtained with this algorithm. Thus, XPCT can detect subtle changes in white-matter microstructure in the course of a neuropathology, as illustrated by our results in the LPC rat model of focal demyelination. This method also seems ideally suited for future phenotype screening of myelin abnormalities in transgenic animals. Another potential application of connectome mapping by XPCT is the need for new imaging tools to cross-validate DTI [46,47]. In particular, XPCT might provide a



reference in regions of crossing fibers, which are typically difficult to resolve on DTI. Additionally, interpretation of DTI metrics in terms of neuronal and non-neuronal cell types might benefit from XPCT solely depiction of myelinated axons.

Another advantage is that XPCT is non-destructive, and dehydration by ethanol is reversible; thus, brain samples remain available for further analysis. After rehydration, we were able to perform our usual histological and immunohistological analyses. Importantly, brain slices did not show overt signs of radiation damage. In addition, ethanol dehydration/rehydration induces less volume variation and brain sample distortion than brain-clearing techniques. Because XPCT gives access to anatomic landmarks, co-registration of X-ray and optical images may be readily obtained. For instance (relevant to our discussion of DTI validation), affine or non-linear co-registration between DTI, XPCT and brain slices immunolabeled for activated glial cells could help decipher the contribution of inflammation to DTI metrics. Ultimately, such pipelines would pave the way to atlas-based analyses of XPCT datasets [48].

Like any technique, XPCT is not devoid of limitations. Propagation-based imaging set-up employed here has some limitations on the quantitativity of the reconstructed phase. Other techniques that can reconstruct quantitatively phase at this resolution [49] emerged only a few years ago (before the imaging campaign) and might even give better contrast between the different tissues. Imaging live brains at such high spatial resolution is not currently an option, because of dosimetry [50] and because the skull interferes with X-ray coherence hence having a high contrast with the brain in situ remains a challenge. Nevertheless, there is no obstacle to imaging postmortem human brains [6,22] or other human tissue [51], which has important implications for anatomopathological studies [42,52]. In addition, a synchrotron X-ray source is currently needed to produce high coherence for phase-contrast imaging, which may be a concern in terms of accessibility. However, producing phase contrast with laboratory and clinical sources is an active field of research that might solve the problem in the near future [53–56]. Finally, XPCT produces large datasets that are not easy to handle and necessitate the development of automatic post-processing tools and pipelines. This was achieved in the current project through a public-private partnership. Here, 3D analyses were performed only locally where animal models exhibited white matter loss, while information was available for the whole brain: in future work, exploitation of whole brain 3D rendering of myelin might provide new insight into white matter injury diseases. In part II of this series of articles, we develop and share a pipeline designed with open-source tools (<https://zenodo.org/record/4584753>) to segment amyloid- $\beta$  plaques and extract 3D morphometric parameters in different animal models of Alzheimer's disease [12]. The development of such end-user-friendly workflows is crucial to allow widespread use of XPCT in the neuroscience community. Collaborative efforts by multidisciplinary teams will be crucial to boosting innovation in the field of novel X-ray imaging techniques and to fostering discoveries that will ultimately benefit patients with white-matter injuries.

## 5. Conclusion

The proposed XPCT approach enables brain-wide studies of myelinated fiber tracts and of their microstructural changes in neurological diseases. Fiber directions and anisotropy metrics were retrieved from XPCT data. This is achieved with conventional animals (i.e., no need for fluorescent reporter mice), minimal sample preparation, and fast acquisition, thus allowing high throughput analysis. Furthermore, XPCT was compatible with subsequent conventional histology of brain samples. To date, the main limitation is represented by synchrotron accessibility; however, transfer of this technology to conventional X-ray sources accessible to standard laboratories is under active development [57]. In the future, combining different imaging techniques with different resolution levels and complementary information will push the frontiers of our understanding of brain structure and function.

**Funding.** Labex PRIMES (ANR-11-IDEX-0007, ANR-11-LABX-0063); European Synchrotron Radiation Facility

(LS2292, MD1018, MD1094, MD1106, MD1125); Agence Nationale de la Recherche (Breakthru (ANR-18-CE19-0003), NanoBrain (ANR15-CE18-0026), NeoRepair (ANR-17-CE16-0009)).

**Acknowledgments.** This work was performed within the framework of LABEX PRIMES (ANR-11-LABX-0063) of Université de Lyon, within the "Investissements d'Avenir" program (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR). The MRI part of the study was performed on CERMEP imaging facilities (<http://www.cermep.fr>, Lyon, France). The authors would like to thank Jean-Baptiste Langlois from CERMEP for animal preparation and MRI acquisition and Corinne Perrin from the Tumorothèque Est tissue bank, CRB-HCL (Lyon, France), for managing human brain samples. We thank Clément Tavakoli for designing Fig. S1. The authors would like to thank our local ESRF contacts Lukas Helfen and Vincent Fernandez, as well as Max Langer, Loriane Weber and David Rousseau for participating in XPCT data acquisition at ESRF. This work was supported by the ESRF by allocation of beam time (LS2292, MD1018, MD1094, MD1106, MD1125). The research was funded by the French national research agency (ANR) NanoBrain (ANR15-CE18-0026), and Breakthru (ANR-18-CE19-0003). LF is supported by ANR NeoRepair (ANR-17-CE16-0009).

#### Authors' contributions (according to Contributor Role Taxonomy (CRediT))

- Conceptualization: MW, FC
- Data curation: MC, EB, HR, MW, FC
- Formal analysis: MC, AA
- Funding acquisition: EB, FP, MW, FC
- Investigation: HR, EO, VH, AP, CCdS, LF, OR, RB, EB, CO, FP, FC, MW
- Methodology: EB, HR, MW, FC
- Project administration: MW, FC
- Resources: BF, DM
- Software: AA, BF
- Supervision: EB, FC, MW
- Validation: MC, HE, FP, FC, MW
- Visualization: MC
- Writing – original draft: MW
- Writing – review & editing: MC, FP, HE, HR, MW, FC

**Disclosures.** The authors declare no conflicts of interest.

**Data availability.** The XPCT raw data cannot be shared at this time due to the large size of the datasets, but can be made available on reasonable request. The DTI-like algorithm is the property of NOVITOM.

**Supplemental document.** See [Supplement 1](#) for supporting content.

#### References

1. W. S. Tae, B. J. Ham, S. B. Pyun, S. H. Kang, and B. J. Kim, "Current clinical applications of diffusion-tensor imaging in neurological disorders," *J. Clin. Neurol.* **14**, 129–140 (2018).
2. W. Y. Aung, S. Mar, and T. L. Benzinger, "Diffusion tensor MRI as a biomarker in axonal and myelin damage," *Imaging in Medicine* **5**, 427–440 (2013).
3. J. Zhuo, S. Xu, J. L. Proctor, R. J. Mullins, J. Z. Simon, G. Fiskum, and R. P. Gullapalli, "Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury," *NeuroImage* **59**, 467–477 (2012).
4. M. Aswendt, M. Schwarz, W. M. Abdelmoula, J. Dijkstra, and S. Dedeurwaerdere, "Whole-brain microscopy meets in vivo neuroimaging: techniques, benefits, and limitations," *Mol. Imaging Biol.* **19**, 1–9 (2017).
5. E. H. Chang, M. Argyelan, M. Aggarwal, T.-S. S. Chandon, K. H. Karlsgodt, S. Mori, and A. K. Malhotra, "The role of myelination in measures of white matter integrity: Combination of diffusion tensor imaging and two-photon microscopy of CLARITY intact brains," *NeuroImage* **147**, 253–261 (2017).
6. M. Georgiadis, A. Schroeter, Z. Gao, M. Guizar-Sicairos, D. S. Novikov, E. Fieremans, and M. Rudin, "Retrieving neuronal orientations using 3D scanning SAXS and comparison with diffusion MRI," *NeuroImage* **204**, 116214 (2020).
7. J. Albers, S. Pacilé, M. A. Markus, M. Wiart, G. Vande Velde, G. Tromba, and C. Dullin, "X-ray-based 3D virtual histology-adding the next dimension to histological analysis," *Mol. Imaging Biol.* **20**, 732–741 (2018).
8. Y. Hwu, G. Margaritondo, and A.-S. Chiang, "Q&A: Why use synchrotron x-ray tomography for multi-scale connectome mapping?" *BMC Biol.* **15**, 122 (2017). Number: 1.
9. M. Marinescu, M. Langer, A. Durand, C. Olivier, A. Chabrol, H. Rositi, F. Chauveau, T. H. Cho, N. Nighoghossian, Y. Berthezène, F. Peyrin, and M. Wiart, "Synchrotron radiation X-ray phase micro-computed tomography as a new method to detect iron oxide nanoparticles in the brain," *Mol. Imaging Biol.* **15**, 552–559 (2013). Number: 5.

10. H. Rositi, C. Frindel, M. Langer, M. Wiart, C. Olivier, F. Peyrin, and D. Rousseau, "Information-based analysis of X-ray in-line phase tomography with application to the detection of iron oxide nanoparticles in the brain," *Opt. Express* **21**, 27185–27196 (2013).
11. H. Rositi, C. Frindel, M. Wiart, M. Langer, C. Olivier, F. Peyrin, and D. Rousseau, "Computer vision tools to optimize reconstruction parameters in x-ray in-line phase tomography," *Phys. Med. Biol.* **59**, 7767–7775 (2014).
12. M. Chourrout, M. Roux, C. Boisvert, C. Gislar, D. Legland, I. Arganda-Carreras, C. Olivier, F. Peyrin, H. Boutin, N. Rama, T. Baron, D. Meyronet, E. Brun, H. Rositi, M. Wiart, and F. Chauveau, "Brain virtual histology with X-ray phase-contrast tomography Part II: 3D morphologies of amyloid- $\beta$  plaques in Alzheimer's disease models," *Biomed. Opt. Express* **13**, 1640–1653 (2022).
13. F. Chauveau, S. Moucharrafi, M. Wiart, J.-C. Brisset, Y. Berthezène, N. Nighoghossian, and T.-H. Cho, "In vivo MRI assessment of permanent middle cerebral artery occlusion by electrocoagulation: pitfalls of procedure," *Exp & Trans Stroke Med* **2**, 4 (2010).
14. J. Scafidi, T. R. Hammond, S. Scafidi, J. Ritter, B. Jablonska, M. Roncal, K. Szigeti-Buck, D. Coman, Y. Huang, R. J. McCarter, F. Hyder, T. L. Horvath, and V. Gallo, "Intranasal epidermal growth factor treatment rescues neonatal brain injury," *Nature* **506**, 230–234 (2014).
15. M. Zhang, G. Hugon, C. Bouillot, R. Bolbos, J.-B. Langlois, T. Billard, F. Bonnefoi, B. Li, L. Zimmer, and F. Chauveau, "Evaluation of myelin radiotracers in the lysolecithin rat model of focal demyelination: beware of pitfalls!" *Contrast Media & Molecular Imaging* **2019**, 9294586 (2019).
16. B. Nait-Oumesmar, L. Decker, F. Lachapelle, V. Avellana-Adalid, C. Bachelin, and A. B.-. Van Evercooren, "Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination: Oligodendrocyte differentiation in adult SVZ," *European Journal of Neuroscience* **11**, 4357–4366 (1999).
17. K. Chung, J. Wallace, S.-Y. Kim, S. Kalyanasundaram, A. S. Andalman, T. J. Davidson, J. J. Mirzabekov, K. A. Zalocusky, J. Mattis, A. K. Denisin, S. Pak, H. Bernstein, C. Ramakrishnan, L. Grose, V. Gradinaru, and K. Deisseroth, "Structural and molecular interrogation of intact biological systems," *Nature* **497**, 332–337 (2013). Number: 7449.
18. D. Paganin, S. C. Mayo, T. E. Gureyev, P. R. Miller, and S. W. Wilkins, "Simultaneous phase and amplitude extraction from a single defocused image of a homogeneous object," *J Microsc* **206**, 33–40 (2002). Number: Pt 1.
19. A. F. Frangi, W. J. Niessen, K. L. Vincken, and M. A. Viergever, "Multiscale vessel enhancement filtering," in *Medical Image Computing and Computer-Assisted Intervention—MICCAI'98*, vol. 1496, W. M. Wells, A. Colchester, and S. Delp, eds. (Springer Berlin Heidelberg, 1998), pp. 130–137. Series Title: Lecture Notes in Computer Science.
20. M. Sato, I. Bitter, M. Bender, A. Kaufman, and M. Nakajima, "TEASAR: tree-structure extraction algorithm for accurate and robust skeletons," in *Proceedings the Eighth Pacific Conference on Computer Graphics and Applications* (IEEE Comput. Soc., 2000), pp. 281–449.
21. G. E. Barbone, A. Bravin, P. Romanelli, A. Mittone, D. Bucci, T. Gaaß, G. Le Duc, S. Auweter, M. F. Reiser, M. J. Kraiger, M. Hrabe de Angelis, G. Battaglia, and P. Coan, "Micro-imaging of brain cancer radiation therapy using phase-contrast computed tomography," *International Journal of Radiation Oncology, Biology, Physics* **101**, 965–984 (2018). Number: 4.
22. M. Töpferwien, M. Krenkel, D. Vincenz, F. Stöber, A. M. Oelschlegel, J. Goldschmidt, and T. Salditt, "Three-dimensional mouse brain cytoarchitecture revealed by laboratory-based x-ray phase-contrast tomography," *Sci Rep* **7**, 42847 (2017).
23. M. Saccomano, J. Albers, G. Tromba, M. Dobrivojevic Radmilovic, S. Gajovic, F. Alves, and C. Dullin, "Synchrotron inline phase contrast  $\mu$ CT enables detailed virtual histology of embedded soft-tissue samples with and without staining," *J Synchrotron Rad* **25**, 1153–1161 (2018).
24. Y. Ren, Y. Wang, G. Zhou, Y. He, H. Xie, G. Du, B. Deng, X. Lin, G.-y. Yang, and T. Xiao, "X-ray propagation-based equally sloped tomography for mouse brain," *Journal of X-Ray Science and Technology* **24**, 79–86 (2016).
25. J. S. O'Brien and E. L. Sampson, "Lipid composition of the normal human brain: gray matter, white matter, and myelin," *XST* **6**, 537–544 (1965).
26. L.-Y. Zhang, P. Lin, J. Pan, Y. Ma, Z. Wei, L. Jiang, L. Wang, Y. Song, Y. Wang, Z. Zhang, K. Jin, Q. Wang, and G.-Y. Yang, "CLARITY for High-resolution Imaging and Quantification of Vasculature in the Whole Mouse Brain," *Aging and disease* **9**, 262 (2018).
27. C. Leuze, M. Goubran, M. Barakovic, M. Aswendt, Q. Tian, B. Hsueh, A. Crow, E. Weber, G. Steinberg, M. Zeineh, E. Plowey, A. Daducci, G. Innocenti, J.-P. Thiran, K. Deisseroth, and J. McNab, "Comparison of diffusion MRI and CLARITY fiber orientation estimates in both gray and white matter regions of human and primate brain," *NeuroImage* **228**, 117692 (2021).
28. M. Morawski, E. Kirilina, N. Scherf, C. Jäger, K. Reimann, R. Trampel, F. Gavrilidis, S. Geyer, B. Biedermann, T. Arendt, and N. Weiskopf, "Developing 3D microscopy with CLARITY on human brain tissue: towards a tool for informing and validating MRI-based histology," *NeuroImage* **182**, 417–428 (2018).
29. M. Krause, J. M. Hausherr, B. Burgeth, C. Herrmann, and W. Krenkel, "Determination of the fibre orientation in composites using the structure tensor and local X-ray transform," *J Mater Sci* **45**, 888–896 (2010).
30. S. Mikula, J. Binding, and W. Denk, "Staining and embedding the whole mouse brain for electron microscopy," *Nat Methods* **9**, 1198–1201 (2012). Number: 12.

31. R. A. Salo, I. Belevich, E. Manninen, E. Jokitalo, O. Gröhn, and A. Sierra, "Quantification of anisotropy and orientation in 3D electron microscopy and diffusion tensor imaging in injured rat brain," *NeuroImage* **172**, 404–414 (2018).
32. T. Jensen, M. Bech, O. Bunk, A. Menzel, A. Bouchet, G. Le Duc, R. Feidenhans'l, and F. Pfeiffer, "Molecular X-ray computed tomography of myelin in a rat brain," *NeuroImage* **57**, 124–129 (2011). Number: 1.
33. M. Georgiadis, A. Schroeter, Z. Gao, M. Guizar-Sicairos, M. Liebi, C. Leuze, J. A. McNab, A. Balolia, J. Veraart, B. Ades-Aron, S. Kim, T. Shepherd, C. H. Lee, P. Walczak, S. Chodankar, P. DiGiacomo, G. David, M. Augath, V. Zerbi, S. Sommer, I. Rajkovic, T. Weiss, O. Bunk, L. Yang, J. Zhang, D. S. Novikov, M. Zeineh, E. Fieremans, and M. Rudin, "Nanostructure-specific X-ray tomography reveals myelin levels, integrity and axon orientations in mouse and human nervous tissue," *Nat Commun* **12**, 2941 (2021).
34. M. Wiecek, F. Schaff, C. Jud, D. Pfeiffer, F. Pfeiffer, and T. Lasser, "Brain connectivity exposed by anisotropic X-ray dark-field tomography," *Sci Rep* **8**, 14345 (2018). Number: 1.
35. L. Bailly, T. Cochereau, L. Orgéas, N. Henrich Bernardoni, S. Rolland du Roscoat, A. McLeer-Florin, Y. Robert, X. Laval, T. Laurencin, P. Chaffanjon, B. Fayard, and E. Boller, "3D multiscale imaging of human vocal folds using synchrotron X-ray microtomography in phase retrieval mode," *Sci Rep* **8**, 14003 (2018).
36. J. Dudak, J. Zemlicka, J. Karch, M. Patzelt, J. Mrzilkova, P. Zach, Z. Hermanova, J. Kvacek, and F. Krejci, "High-contrast X-ray micro-radiography and micro-CT of ex-vivo soft tissue murine organs utilizing ethanol fixation and large area photon-counting detector," *Sci Rep* **6**, 30385 (2016). Number: 1.
37. M. Reichardt, J. Frohn, A. Khan, F. Alves, and T. Salditt, "Multi-scale X-ray phase-contrast tomography of murine heart tissue," *Biomed. Opt. Express* **11**, 2633–2651 (2020).
38. R. Shirai, T. Kunii, A. Yoneyama, T. Oozumi, H. Maruyama, T.-T. Lwin, K. Hyodo, and T. Takeda, "Enhanced renal image contrast by ethanol fixation in phase-contrast X-ray computed tomography," *J Synchrotron Rad* **21**, 795–800 (2014). Number: 4.
39. J. Missbach-Guentner, D. Pinkert-Leetsch, C. Dullin, R. Ufartes, D. Hornung, B. Tampe, M. Zeisberg, and F. Alves, "3D virtual histology of murine kidneys—high resolution visualization of pathological alterations by micro computed tomography," *Sci Rep* **8**, 1407 (2018). Number: 1.
40. M. Töpferwien, A. Markus, F. Alves, and T. Salditt, "Contrast enhancement for visualizing neuronal cytoarchitecture by propagation-based x-ray phase-contrast tomography," *NeuroImage* **199**, 70–80 (2019).
41. M.-Q. Zhang, L. Zhou, Q.-F. Deng, Y.-Y. Xie, T.-Q. Xiao, Y.-Z. Cao, J.-W. Zhang, X.-M. Chen, X.-Z. Yin, and B. Xiao, "Ultra-high-resolution 3D digitalized imaging of the cerebral angioarchitecture in rats using synchrotron radiation," *Sci Rep* **5**, 14982 (2015). Number: 1.
42. L. Massimi, I. Bukreeva, G. Santamaria, M. Fratini, A. Corbelli, F. Brun, S. Fumagalli, L. Maugeri, A. Pacureanu, P. Cloetens, N. Pieroni, F. Fiordaliso, G. Forloni, A. Uccelli, N. Kerlero de Rosbo, C. Balducci, and A. Cedola, "Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ," *NeuroImage* **184**, 490–495 (2019).
43. L. Massimi, N. Pieroni, L. Maugeri, M. Fratini, F. Brun, I. Bukreeva, G. Santamaria, V. Medici, T. E. Poloni, C. Balducci, and A. Cedola, "Assessment of plaque morphology in Alzheimer's mouse cerebellum using three-dimensional X-ray phase-based virtual histology," *Sci Rep* **10**, 11233 (2020). Number: 1.
44. M. A. Marin and S. T. Carmichael, "Mechanisms of demyelination and remyelination in the young and aged brain following white matter stroke," *Neurobiology of Disease* **126**, 5–12 (2019).
45. H. Chen, T. Liu, Y. Zhao, T. Zhang, Y. Li, M. Li, H. Zhang, H. Kuang, L. Guo, J. Z. Tsien, and T. Liu, "Optimization of large-scale mouse brain connectome via joint evaluation of DTI and neuron tracing data," *NeuroImage* **115**, 202–213 (2015).
46. T. B. Dyrby, G. M. Innocenti, M. Bech, and H. Lundell, "Validation strategies for the interpretation of microstructure imaging using diffusion MRI," *NeuroImage* **182**, 62–79 (2018).
47. M. Andersson, H. M. Kjer, J. Rafael-Patino, A. Pacureanu, B. Pakkenberg, J.-P. Thiran, M. Ptito, M. Bech, A. Bjorholm Dahl, V. Andersen Dahl, and T. B. Dyrby, "Axon morphology is modulated by the local environment and impacts the noninvasive investigation of its structure–function relationship," *Proc Natl Acad Sci USA* **117**, 33649–33659 (2020).
48. C. J. Niedworok, A. P. Y. Brown, M. Jorge Cardoso, P. Osten, S. Ourselin, M. Modat, and T. W. Margrie, "aMAP is a validated pipeline for registration and segmentation of high-resolution mouse brain data," *Nat Commun* **7**, 11879 (2016). Number: 1.
49. M.-C. Zdora, P. Thibault, W. Kuo, V. Fernandez, H. Deyhle, J. Vila-Comamala, M. P. Olbinado, A. Rack, P. M. Lackie, O. L. Katsamenis, M. J. Lawson, V. Kurtcuoglu, C. Rau, F. Pfeiffer, and I. Zanette, "X-ray phase tomography with near-field speckles for three-dimensional virtual histology," *Optica* **7**, 1221 (2020).
50. Y. Prezado, M. Vautrin, I. Martínez-Rovira, A. Bravin, F. Estève, H. Elleaume, P. Berkvens, and J. F. Adam, "Dosimetry protocol for the forthcoming clinical trials in synchrotron stereotactic radiation therapy (SSRT): dosimetry protocol for the clinical trials in SSRT," *Med. Phys.* **38**, 1709–1717 (2011).
51. H. Rougé-Labriet, S. Berujon, H. Mathieu, S. Bohic, B. Fayard, J.-N. Ravey, Y. Robert, P. Gaudin, and E. Brun, "X-ray phase contrast osteo-articular imaging: a pilot study on cadaveric human hands," *Sci. Rep.* **10**, 1911 (2020).
52. A. Cedola, A. Bravin, I. Bukreeva, M. Fratini, A. Pacureanu, A. Mittone, L. Massimi, P. Cloetens, P. Coan, G. Campi, R. Spanò, F. Brun, V. Grigoryev, V. Petrosino, C. Venturi, M. Mastrogiacomo, N. Kerlero de Rosbo, and A. Uccelli,

- “X-ray phase contrast tomography reveals early vascular alterations and neuronal loss in a multiple sclerosis model,” *Sci Rep* **7**, 5890 (2017). Number: 1.
53. L. Birnbacher, M. Willner, A. Velroyen, M. Marschner, A. Hipp, J. Meiser, F. Koch, T. Schröter, D. Kunka, J. Mohr, F. Pfeiffer, and J. Herzen, “Experimental realisation of high-sensitivity laboratory x-ray grating-based phase-contrast computed tomography,” *Sci Rep* **6**, 24022 (2016).
54. H. Rougé-Labriet, L. Quenot, S. Bohic, B. Fayard, D. M. Paganin, E. Brun, and S. Berujon, “Comparison of X-ray speckle based imaging deflection retrieval algorithms for the optimization of radiation dose,” *Phys. Medicine & Biol.* **66**, 065005 (2020).
55. D. H. Larsson, W. Vågberg, A. Yaroshenko, A. O. Yildirim, and H. M. Hertz, “High-resolution short-exposure small-animal laboratory x-ray phase-contrast tomography,” *Sci Rep* **6**, 39074 (2016).
56. T. Zhou, U. Lundström, T. Thüring, S. Rutishauser, D. H. Larsson, M. Stampanoni, C. David, H. M. Hertz, and A. Burvall, “Comparison of two x-ray phase-contrast imaging methods with a microfocus source,” *Opt. Express* **21**, 30183 (2013).
57. L. Quenot, H. Rougé-Labriet, S. Bohic, S. Berujon, and E. Brun, “Implicit tracking approach for X-ray phase-contrast imaging with a random mask and a conventional system,” *Optica* **8**, 1412–1415 (2021).